XmAb 657
Alternative Names: XmAb-657Latest Information Update: 03 Nov 2024
Price :
$50 *
At a glance
- Originator Xencor
- Class Bispecific antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 09 Sep 2024 Preclinical trials in Autoimmune disorders in USA (Parenteral)
- 09 Sep 2024 Pharmacokinetics, pharmacodynamics and adverse events data from preclinical trial in Autoimmune disorders released by Xencor
- 09 Sep 2024 Xencor plans to initiate a first-in-human study in Autoimmune disorders (Parenteral), in the second half of 2025